Latest News “Nature Biotechnology: COVID-19 long haulers” Click here. “Ampio gets promising data on drug that could be used to treat COVID” Click here. Ampio Pharmaceuticals Strengthens Management Team and Board of DirectorsDate: October 13, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in IndiaDate: September 21, 2021 | READ MORE > Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)Date: September 15, 2021 | READ MORE > Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of ActionDate: August 13, 2021 | READ MORE > Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual MeetingDate: August 12, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesDate: August 11, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateDate: August 4, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual MeetingDate: July 29, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)Date: July 28, 2021 | READ MORE > Ampio Pharmaceuticals to Present at Aspen Lung ConferenceDate: July 27, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business UpdateDate: July 14, 2021 | READ MORE > Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory DistressDate: June 25, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® IndexDate: June 18, 2021 | READ MORE > Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAKDate: June 17, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to IndiaDate: June 15, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Summer Healthcare SymposiumDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and ExpoDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International CongressDate: May 21, 2021 | READ MORE > Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)Date: May 10, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business UpdateDate: May 5, 2021 | READ MORE >
